BSA reagent pH5 grade is a highly purified, lyophilized powder, it has a pH of ≈5 when dissolved in water.
| SPECIFICATION - Bovine Serum Albumin - Reagent Grade pH 5 (BSA-5) | |
| Product | Bovine Serum Albumin- Reagent Grade pH 5 |
| Catalogue No. | BSA5 |
| Certificate of Suitability | Australia: R1-CEP 2005-191-Rev 00New Zealand: R1-CEP 2003-205-Rev 00 |
| Source | Bovine plasma from healthy animals inspected ante and post mortem by New Zealand or Australian Government veterinarians and passed as fit for human consumption |
| Collection/Processing Method | Cohn Fraction V Purified by heat shock treatment with charcoal treatment and diafiltrarion. |
| Description | Off white to pale green / yellow lyophilised powder |
| Stability | Stable for a minimum of 5 years under correct storage conditions |
| Storage | Store in sealed containers with a desiccant under dry conditions between 2 - 8°C |
| Analysis | Method | Range |
| pH | pH meter | 4.8 - 5.2 |
| Albumin | Gel Electrophoresis | ≥ 98% |
| Protein | LECO CF003.1 (dry basis) | ≥ 96% |
| Moisture Content | Oven Moisture Content | ≤ 5.0% |
| Chloride | Coulometric | ≤ 0.15% |
| Calcium | ICP-OES | ≤ 0.05% |
| Iron | ICP-OES | ≤ 0.002% |
| Magnesium | ICP-OES | ≤ 0.005% |
| Phosphorus, inorganic | Coulometric | ≤ 0.005% |
| Potassium | ICP-OES | ≤ 0.015% |
| Sodium | ICP-OES | ≤ 0.08% |
| Lead | ICP-OES | ≤ 0.003% |
| Ash Content | Gravimetric | ≤ 2.5% |
| Optical Density | Abs 405nm at 60mg/ml sol | ≤ 0.2 |
| Solubility | 60mg/ml sol. | Soluble |
| Bioburden | Heterotrophic Colony count - pour plate | ≤ 100 CFU/g |
EDQM
The European Directorate for the Quality of Medicines (EDQM) has originated from the European Pharmacopoeia Secretariat which, with the addition of new responsibilities changed its name to the European Department for the Quality of Medicines (EDQM). The EDQM sits alongside the European Medicines Agency (EMEA).
Amongst other activities, the EDQM is responsible for the European Pharmacopeia and the issuing of Certificates of Suitability (CEP).
Certificates of Suitability (CEP) are recognised by all signatory states of the European Pharmacopoeia Convention and by the European Union. Other countries have also chosen to recognise them. In the case of Fetal Bovine Serum and other Bovine Serum a CEP can be used by the manufacturers of Fetal Bovine Serum and other Bovine Serum which is intended for use in the manufacture of pharmaceutical products to demonstrate compliance with the Bovine Serum monographs of the European Pharmacopoeia and the EDQM requirements for substances concerned by TSE risk.
The discovery of Bovine Spongiform Encephalopathy (BSE), which is one of a group of similar infections now referred to as Transmissible Spongiform Encephalopathies (TSEs), and it’s spread over many countries of the European Union as well as its discovery in Canada, the USA and Japan is well known. The European events provided the impetus for the Council of Europe Public Health Committee (CEPHC) to pass Resolution AP-CSP (99) 5 addressing the TSE concerns and creating a Certificate of Suitability (COS) pursuant to Directive 75/318/EEC.
The granting of a CoS to a manufacturer, for a particular product, certifies that the product in question has been assessed for the level of risk of transmission of TSEs, and that the risk level is considered low enough that the product is certified as suitable for use in the manufacture of medicinal products in the European Union.
The process of approval requires the manufacturer to submit a dossier that covers all relevant aspects of the collection of raw material and further processing that is performed to reach the product that is offered to end users. This dossier is detailed and covers the specific material that is collected, the collection method, process validation, testing, traceability, quality systems and an expert review.
Only after this dossier has been examined and approved by two rapporteurs and, if necessary, by a panel of experts appointed by the European Directorate for the Quality of Medicines (EDQM) is the manufacturer granted a COS.
Moregate Biotech has been granted a COS for:
- Fetal Bovine Serum – Australian Origin – CEP2000-187
- Fetal Bovine Serum – New Zealand Origin – CEP2000-188
- Adult Bovine Serum - New Zealand Origin – CEP2001-093
- Adult Bovine Serum (Defibrinated) - New Zealand Origin – CEP2000-174
- Bovine Plasma – New Zealand Origin – CEP2003-199
- Bovine Serum Albumin – manufactured in Australia from New Zealand origin Bovine Plasma – CEP2003-205
- Bovine Plasma – Australian Origin - CEP 2005-192
- Bovine Serum Albumin – manufactured in Australia from Australian origin Bovine Plasma - CEP 2005-191
Copies of the Certificates of Suitability are available upon request
Hazards Identification
SPECIAL INDICATION OF HAZARDS TO HUMANS AND THE ENVIRONMENT
- Not hazardous.
First Aid Measures
Get Medical attention immediately.
Inhalation
If inhaled, remove to fresh air. If breathing becomes difficult, call a physician
Ingestion
If swallowed, give several glasses of water to drink to dilute.
Skin Contact
Wash skin with soap and copious amounts of water.
Eye Contact
Flush with water for at least 15 minutes, lifting upper and lower eyelids occasionally.
Procedures for Personal Precaution
Exercise appropriate precautions to minimize direct contact with skin or eyes.
Methods for Cleaning Up
Mop up
Ventilate area and wash spill site after material pickup is complete
Fire fighting Measures
Extinguishing Media
Water spray. Carbon dioxide, dry chemical powder, or appropriate foam.
Special Risks
Emits toxic fumes under fire conditions
Special Protective Equipment for Firefighters
Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.
Accidental Release
Procedures for Personal Precaution
Exercise appropriate precautions to minimize direct contact with skin or eyes.
Methods for Cleaning Up
Mop up
Ventilate area and wash spill site after material pickup is complete
Handling and Storage
Handling
Avoid contact with eyes, skin and clothing.
Storage
Keep tightly closed. Store at 2 - 8 °C.
Exposure Controls / Personal Protection
- Wash thoroughly after handling.
- Wear dust mask
- Protective gloves
- Chemical safety goggles
Disposal Considerations
Contact a licensed professional waste disposal service to dispose of this material.
Transport Information
- Non-hazardous for road transport
- Non-hazardous for sea transport
- Non-hazardous for air transport
Note: The above information is believed to be correct, but shall be used as a guide only.
Disclaimer: For pharmaceutical use only.
BOVINE SERUM ALBUMIN
Moregate Bovine Serum Albumin BSA is manufactured from Bovine Plasma of Australian or New Zealand origin in a well equipped facility located in Bulimba, Australia. The manufacturing process is a modified Heat Shock method.
The process includes ultrafiltration, micro filtration and freeze-drying.
Trained personnel following Standard Operating Procedures perform all operations. Each batch has a Manufacturing Record, which is reviewed after batch completion.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
关于一般所说的血清,在这大约要先分清楚什么叫血清,什么叫单抗治疗剂(在大陆医院及一般人也叫血清)
血清,如果正常而言是从病患犬只身上抽取血液而提炼制成的一种抗体,例如从一只患有犬瘟的患犬经过长期治疗痊愈后,将他的血液抽取出来,经过粹取提炼,而这种提炼出来的血清(免疫抗体),是有治疗加预防犬瘟的效果,同样包括其它另5种致命性病毒如细小肠炎,犬勾螺旋病毒,犬肝炎,犬黄胆等也同样是这样提炼,但是患犬经过治疗痊愈性低而且提炼血清需要大量的血液才能提炼(例如500ml的血液才经过筛检提炼为2.8ml的血清,而一只患犬需要注射治疗预防是需要2.5mlX5剂,试问这种高消耗经济成本时间的脆取提炼法,谁愿意去做)
因此早期国外会将犬只的各种致命性病毒,注射入牛,马,羊,猪等足蹄类动物身体内,再藉由这些动物的血液来脆取提炼犬病毒血清(这些病毒会在这些足蹄类动物身上起一些作用,但却不会致命!而这些动物的血液也够多够充沛来做提炼),经过多年试验中以羊只的血液提炼血清是比较有效果的!
而目前大陆中也是采用相同的方式提炼血清,但是实验对象包括牛马猪羊等足蹄动物,而再粹取血清的过程除了提炼过程严谨也要有相当的保存过程,这两者只要有一个环节有不当,提炼出的血清就会产生极大的不稳定性甚至于无效!!!
这也就是我们常说血清的由来,因为粹取对像非犬只类,加上或许运送或保存或粹取过程(这都是我们无法见到及预期的可変因素)因此血清的作用几乎就大打折扣了,一般使用血清是用于幼中期犬集体长途运输,或是对于一些大犬只因某些原因不能注射疫苗而又需要加强自身免疫时就需要注射(血清是属于一种短暂时提升免疫体的做法),而真正正本清源,是等小狗或大狗身体健康时,注射2-3剂疫苗来确定自身免疫预防!!
也就是说,很多医生或宠物店会因为不完全了解小狗自身情况如何之前,会给狗狗注射血清,希望提高狗狗的免疫抗体,而等狗狗身体和情绪稳定,再开始接种疫苗,但是,前文中也提过,有太多不可预期性会发生,如小狗太早断奶或母乳不足,血清自身因保存或运输不当!这些太多不确定因素造成血清无效外,更容易害了犬只!!
过来我们谈单抗治疗剂,这种疗剂我们称为单抗疫苗(根据犬只患病不同而施以不同的单病毒对抗疗剂,例如犬瘟单抗,细小单抗),这是属于人工合成的活化菌体,其实也很像疫苗指是因为合成为比疫苗更微弱毒性,它是需要一连施打4-5剂,才有作用的针剂,它的作用我大约解释一下,这种抗体是经过人工更弱化的病毒,而注入患犬体内是激发狗狗自身免疫力对这种病毒进行适应力而加以消灭,因此需要施打五剂,等狗狗自身免疫被激发对这种病毒产生抵抗力(排斥性),
狗自生免疫系统就会针对侵入的单种病毒进行围剿消灭,而等自身免疫力能消灭侵入病毒后,狗的身体内这单种病毒病也就会痊愈(当然这只是针对单一种病毒而言,而患病犬只通常并发并非单一种病症,因此要确实诊断使用支持对症诊疗法举个例,如犬瘟并发呼吸道葡萄球链菌引发流鼻涕咳嗽症状,既使犬瘟病毒被消灭但是葡萄球链菌并不会因犬瘟病毒被消灭而停止作怪,医生还是要针对葡萄链球菌作抗生素注射治疗),而痊愈后的狗,自生免疫力会对单一病毒产生终生排斥作用,例如犬只经过细小治愈后,这只狗终身对细小病毒免疫,既使给狗只注射六联疫苗,疫苗内的弱化细小病毒一样被狗狗自身免疫力排斥消灭,而其它五种疫苗却会再犬只身上起作用(既使得犬瘟医治好的狗能终生预防犬瘟,也同样要打疫苗,因为致命性病毒不是只有犬瘟一种,除非你加狗狗天生利害能六种病都得到而又都医治好!这种可能性太低也千万保佑别这么做狗狗和饲主都太辛苦)!
这也就是为什么患病犬只到医院被确诊为细小或犬瘟时,医生又要打血清的原因(其实是单抗),当然单抗不是万灵丹,它只是加强犬只自身激发免疫的一种催化剂,若是犬只本身体质虚弱或是病毒已经大面积侵犯犬只器官,这些治疗方式都只是一种尽人事听天命的方法了!!!
想做临床的血标本的一些代谢组学研究，不知道应该用血浆还是血清，大家的说法好像也不太一致，请大神指导啊，最好有些参考文献，谢谢！
Nutrients.2017May10;9(5).
ClinicalSignificanceandPrognosticEffectofSerum25-hydroxyvitaminDConcentrationsinCriticalandSevereHand,FootandMouthDisease.
手足口病危重儿血清25-羟维生素D浓度的临床意义与预后影响
作者党红星，刘成军，李静，程时骄，许峰
摘要
Abstract
目的：探讨血清25羟维生素D[25（OH)D]浓度与手足口病危重症的关系及评估手足口病危重儿血清25-羟维生素D浓度的临床意义与预后影响。
OBJECTIVE:
Toexaminetheassociationofserum25-hydroxyvitaminD[25(OH)D]concentrationswithcriticalandseverehand,footandmouthdisease(HFMD)andassesstheclinicalsignificanceandprognosticeffectof25(OH)DconcentrationsinchildrenwithHFMD.
方法：本研究为前瞻性观察研究。
METHODS:
ThisisaProspectiveobservationalstudy.
将138例手足口病患儿分为普通组（49例）、重症组（52例）和危重组（37例）。另选取同期门诊体检的59例健康儿童作为对照组。
The138childrenwithHFMDweredividedintocommon(49cases),severe(52cases),andcritical(37cases)HFMDgroups.Another59healthychildrenundergoingoutpatientmedicalexaminationsduringthesameperiodwerechosenasthecontrolgroup.
测定所有对象的血清25（OH）D浓度，每组再分为血清25（OH）D正常组（≥30ng/mL）；不足组（20-29.9ng/mL）；缺乏组（低于20ng/mL）。
Serum25(OH)Dconcentrationsweremeasuredinallthesubjects,andeachgroupwassuBDividedbyserum25(OH)Dconcentrationinto25(OH)Dnormal(≥30ng/mL);insufficiency(20-29.9ng/mL),anddeficiency(<20ng/mL)groups.
手足口病危急重症组在入住儿科ICU（PICU）时记录小儿危重病例评分（PCIS）。
Thepediatriccriticalillnessscore(PCIS)wasrecordedforthecriticalandsevereHFMDgroupuponadmissiontothepediatricintensivecareunit(PICU).
监测小儿危重手足口病患者血乳酸（LAC）、血清钙离子（Ca2+）、D-二聚体（DD）、乳酸脱氢酶（LDH）、肌酸激酶同工酶（CK-MB）水平；脑干脑炎、神经源性肺水肿、循环衰竭的发生情况；14天病死率。
ChildrenwithcriticalandsevereHFMDwerealsomonitoredforbloodlactate(LAC),serumcalciumions(Ca++),D-dimer(DD),lactatedehydrogenase(LDH),andcreatinekinase-MB(CK-MB)levels;theincidencesofbrainstemencephalitis,neurogenicpulmonaryedema,andcirculatoryfailure;andthe14-daymortalityrate.
结果：
RESULTS：
各组血清25（OH）D浓度普遍较低。
Serum25(OH)Dconcentrationsweregenerallylowinallgroups.
与对照组（28.1±6.6ng/mL,8%）、普通组（29.5±8.1ng/mL,10%）和重症组（31.9±9.7ng/mL,8%）相比，危重组患者血清25（OH）D平均浓度（20.0±8.4ng/mL）明显较低，血清25（OH）D缺乏比例（18％）明显较高(P＜0.05）。
ThecriticalHFMDgroupshowedasignificantlylowerserum25(OH)Dmeanconcentration(20.0±8.4ng/mL)andahigherproportionofdeficiency(18%)comparedwiththecontrolgroup(28.1±6.6ng/mL,8%),common(29.5±8.1ng/mL,10%)andsevere(31.9±9.7ng/mL,8%)HFMDgroups(p<0.05).
在危重组中，25（OH）D缺乏组比25（OH）D正常组及不足组具有更低的PCIS值（P＜0.05）；而比后两组具有更高LAC、LDH、CK-MB和DD；具有（更高的）脑干脑炎、神经源性肺水肿、循环衰竭发生率及病死率（P＜0.05）。
InthecriticalandsevereHFMDgroups,the25(OH)DdeficiencygrouphadlowerPCISsthanthe25(OH)Dnormalandinsufficiencygroups(p<0.05);andhadhighervaluesthanthelattertwogroupsforLAC,LDH,CK-MBandDD;andtheincidencesofbrainstemencephalitis,neurogenicpulmonaryedema,circulatoryfailure,andmortality(p<0.05).
死亡组较存活组具有显著降低的血清25（OH）D浓度和PCIS（P＜0.05），具有较高的LAC、LDH、CK-MB和DD水平；较高的脑干脑炎、神经源性肺水肿、循环衰竭发病率（P＜0.05）。
Thedeathgroupshowedsignificantlylowerserum25(OH)DconcentrationsandPCISsthanthesurvivalgroup(p<0.05)andhadhigherLAC,LDH,CK-MBandDDlevelsandhigherincidencesofbrainstemencephalitis,neurogenicpulmonaryedema,andcirculatoryfailure(p<0.05).
Logistic回归分析显示，血清25（OH）D浓度是影响重症手足口病患儿病死率的独立因素。
Logisticregressionanalysisrevealedthattheserum25(OH)DconcentrationwasanindependentfactorthatinfluencedmortalityinchildrenwithcriticalandsevereHFMD.
CONCLUSIONS:
结论：
在这项研究中，我们发现，血清25（OH）D浓度在手足口病危重患儿中大幅降低，并与手足口病的严重程度相关。
Inthisstudy,wefindtheserum25(OH)DconcentrationsaresubstantiallyreducedinchildrenwithcriticalandsevereHFMDandareassociatedwiththeseverityofHFMD.
血清25（OH）D浓度对判断重症手足口病进展和预测死亡风险具有临床价值。
Theserum25(OH)DconcentrationsmayhaveclinicalvaluefordeterminingtheprogressionofcriticalHFMDandpredictingtheriskofdeath.
在确定25（OH）D浓度在手足口病诊断的临床价值之前，仍需进一步的证据。
Furtherevidenceisneededbeforeitcanbestatedthat25(OH)DconcentrationshaveclinicalvalueinHMFDdiagnosis.
关键词：
KEYWORDS:
25-hydroxyvitaminD;criticalillness;footandmouthdisease;hand
25羟维生素D；危重病；手足口病
各位大神，本人实验室小白一枚，现在要保存乙肝病人的血清，以后用来做实验感染细胞。为了最大限度保持病毒的感染活力，应该怎么保存呢？直接-80度冷冻可以吗？需要加甘油吗？
谁的答案详细、真实分就给谁...(勿灌水，否则必究之)
